PLAU and vascular disorder: Iwamoto et al. found that miR-193b targets urokinase-type plasminogen activator (uPA) [158], a molecule involved in vasculopathy that promotes neointimal growth, vascular remodeling, and fibrosis through enhanced ECM degradation [139].